维普期刊资源整合服务平台（V6.5）

79篇 您的检索式：作者名="Shivakumar T"

选中清除导出查看参考文献查看引证文献引用追踪共4页首页上一页第1页下一页末页 /4 跳转

	题名	作者	年代	出处	被引量
1	Perioperative challenges in management of diabetic patients undergoing non-cardiac surgery显示文摘Prediabetes and diabetes are important disease processes which have several perioperative implications.About one third of the United States population is considered to have prediabetes.The prevalence in surgical patients is even higher.This is due to the associated micro and macrovascular complications of diabetes that result in the need for subsequent surgical procedures.A careful preoperative evaluation of diabetic patients and patients at risk for prediabetes is essential to reduce perioperative mortality and morbidity.This preoperative evaluation involves an optimization of preoperative comorbidities.It also includes optimization of antidiabetic medication regimens,as the avoidance of unintentional hypoglycemic and hyperglycemic episodes during the perioperative period is crucial.The focus of the perioperative management is to ensure euglycemia and thus improve postoperative outcomes.Therefore,prolonged preoperative fasting should be avoided and close monitoring of blood glucose should be initiated and continued throughout surgery.This can be accomplished with either analysis in blood gas samples,venous phlebotomy or point-of-care testing.Although capillary and arterial whole blood glucose do not meet standard guidelines for glucose testing,they can still be used to guide insulin dosing in the operating room.Intraoperative glycemic control goals may vary slightly in different protocols but overall the guidelines suggest a glucose range in the operating room should be between 140 mg/dL to 180 mg/dL.When hyperglycemia is detected in the operating room,blood glucose management may be initiated with subcutaneous rapid-acting insulin,with intravenous infusion or boluses of regular insulin.Fluid and electrolyte management are other perioperative challenges.Notably diabetic ketoacidosis and hyperglycemic hyperosmolar nonketotic state are the two most serious acute metabolic complications of diabetes that must be recognized early and treated.	Ursula Galway Praveen Chahar Marc T Schmidt Jorge A Araujo-Duran Jeevan Shivakumar Alparslan Turan Kurt Ruetzler	2021	World Journal of Diabetes2021，12，8：	5
2	The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation显示文摘	SHIVAKUMAR L MINNA J SAKAMAKI T	2002	Mol Cell Biol2002，22，12：	1
3	The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation显示文摘	Shivakumar L Minna J Sakamaki T	2002	Mol Cell Biol2002，22，12：	1
4	The rassfla tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation显示文摘	Shivakumar L Minna J Sakamaki T	2002	Mol Cell Biol2002，22，12：	1
5	The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation显示文摘	Shivakumar L Minna J Sakamaki T	2002	Mol Cell Biol2002，22，12：	1
6	The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation 显示文摘	Shivakumar L Minna J Sakamaki T	2002	Mol Cell Biol2002，22，12：	1
7	The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation显示文摘	Shivakumar L Minna J Sakamaki T	2002	Mol Cell Biol2002，22，12：	1
8	The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin DI accumulation显示文摘	SHIVAKUMAR L MINNA J SAKAMAKI T	2002	Mol Cell Biol2002，22，12：	1
9	The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclinD1 accumulation显示文摘	Shivakumar L Minna J Sakamaki T	2002	Mol Cell Biol2002，22，12：	1
10	The RASSFlA tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation显示文摘	SHIVAKUMAR L MINNA J SAKAMAKI T	2002	Mol Cell Biol2002，22，12：	1
11	The RASSF1 A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation显示文摘	Shivakumar L Minna J Sakamaki T	2002	Mol Cell Biol2002，22，12：	1
12	The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation显示文摘	Shivakumar L Minna J Sakamaki T	2002	Mol Cell Biol2002，22，12：	1
13	Nanoparticles: Complex and multifaceted additives for liquid crystals 显示文摘	SHIVAKUMAR U MIRZAEI J HEGMANN T	2011	Liq- uid Crystals2011，38，1112：	1
14	The RASSFIA tumor suppressor block cell cycle progression and inhibits cyclin D1 accumulation显示文摘	Shivakumar L Minna I Sakamaki T	2002	MoL Cell Biol2002，22，12：	1
15	The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation显示文摘	Minna J Sakamaki T	2002	Mol Cell Biol2002，22，12：	1
16	A case of sensorineural deafness following ingestion of sildenafil 显示文摘	Mukherjee B Shivakumar T	2006	The Journal of Laryngology and Otology2006，121，4：	1
17	A space vector modulation scheme for a dual two-level inverter fed an open-end winding induction motor drive for the elimination of zero sequence currents显示文摘	Somasekhar V T Gopakumar K Shivakumar E G	2002	European Power Electronics and Drives Journal2002，12，2：	1
18	The RASSFIA tumor suppressor blocks cell cycle progression and inhibits cyclinD1 accumulation显示文摘	Shivakumar L Minna J Sakamaki T	2002	Mol Cell Biol2002，22，12：	1
19	Tobias, optimal off-line trajectory planning of hybrid fuel cell/ gas turbine power plants 显示文摘	SHIVAKUMAR Kameswaran BIEGLER L T JUMKER S	2007	American institute of chemical engineers2007，53，2：	1
20	Momentum, business cycle and time-varying expected returns显示文摘	CHORDIA T SHIVAKUMAR L	2002	Journal of Finance2002，57，：	1

返回顶部每页显示：

共4页首页上一页第1页下一页末页 /4 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示